Mr. O’Donnell joined Izun Oral Care in May 2016 as Chief Executive Officer. Previously, he was an Operating Partner with KB Financial/Dana Holdings LLC since 2010. As part of KB/Dana Holdings, he was CEO of Primus Therapeutics; CEO of Matrixx Initiatives, the marketer of Zicam, which he restored to profitability; and CEO of Ducere Pharma, a company formed to acquire a portfolio of OTC brands from Novartis sold to Dr. Reddy’s Labs in May 2016.
Prior to KB/Dana Holdings, Mr. O’Donnell was President of NextWave Pharmaceuticals, a specialty pharma company developing innovative long-acting products later sold to Pfizer for $680MM in milestone payments.
Prior to NextWave, he was CEO of New York Health Care, a Nasdaq-listed healthcare company which he restored to profitability and also CEO of its BioBalance subsidiary where he achieved FDA approval to test a proprietary probiotic licensed from Israel for an orphan drug indication and launched a medical food formulation called Probactrix®.
Previously, he spent 18 years at Wyeth in executive roles ranging from general manager of several business units (with P&L responsibility from $100MM to over $1B) to head of Global Business Development for the OTC business. He also led Wyeth’s Solgar nutraceutical business where he streamlined operations and improved operating margins. At Wyeth, he oversaw the launch of 40 new products generating >$250MM in sales. He started his career as a dermatology sales representative for Bristol Myers.
Mr. O’Donnell is a Registered Pharmacist with a pharmacy degree from St. John’s University and a dual MBA in Marketing & Finance from NYU’s Stern School of Business.
Mr. Talley is CEO of Izun Pharmaceutical Corp. and Chairman of Izun Oral Care with more than 30 years of experience in the industry. Most recently he was the President, CEO and a member of the Board of Directors for Alissa Pharma, LLC a privately held company focused on antibody directed isotopes for various forms of cancer.
Previously he was the CEO, President and a Director of Actinium Pharmaceuticals, Inc. (API) which he took public. Mr. Talley joined API from the position of President, Chief Executive Officer and a Director at EpiCept Corporation which he also took public. Prior to EpiCept, Mr. Talley was the Chief Executive Officer of Consensus Pharmaceuticals, Inc., a biotechnology drug discovery start-up company that developed a proprietary peptide-based combinatorial library screening process.
Prior to joining Consensus, Mr. Talley led Penwest Ltd.’s efforts in its IPO spin-off of its subsidiary Penwest Pharmaceuticals Co. in 1998 and served as President and Chief Operating Officer of Penwest Pharmaceuticals. Penwest was eventually acquired by Endo. Mr. Talley led the alliance between Penwest and Endo.
Mr. Talley started his career at Sterling Drug Inc., where he was responsible for all U.S. marketing activities for prescription drugs when the company was merged with Sanofi, he launched various new pharmaceutical products and participated in the 1988 acquisition of Sterling Drug by Eastman Kodak Co. Mr. Talley received his B.S. in Chemistry from the University of Connecticut and completed coursework towards an M.B.A. in Marketing from New York University, Graduate School of Business.
Dr. Levine is Chairman of Izun Pharmaceutical Corp. and serves as a director & Chief Technology Officer of Izun Oral Care. He also serves as the director and founder of the Jerusalem Perio Center, the largest and foremost private healthcare facility specializing in the treatment of oral diseases and implantology in Israel.
A Diplomate of the American Board of Periodontology with 15 registered patents and numerous patents pending, Dr. Levine is a practicing periodontist with over 25 years of clinical experience, and a frequently featured speaker at international forums on periodontal disease and implantology.
Dr. Levine is an active board member of several hospitals and healthcare centers in Israel. He received his DDS and Certificate of Periodontology at Columbia University, New York.